Company Overview
Assertio Holdings, Inc. operates as a pharmaceutical company dedicated to providing various therapeutic products to patients across the United States, with a specific focus on specialty and generic drug manufacturing. The company functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a business model centered on the research, development, and distribution of medicinal compounds for specific medical conditions. The organization maintains a relatively small operational footprint, employing 53 individuals to support its product portfolio, which includes notable treatments such as INDOCIN for moderate to severe rheumatoid arthritis and acute flares of chronic disease. With a market capitalization of $124.97M and annual revenue of $118.71M, the company's financial scale indicates it holds a mid-tier position within its niche market, reflecting a capitalization that suggests specialized focus rather than mass-market dominance.
Financial Health
The company reported a revenue of $118.71M over the trailing twelve months, yet this top-line figure masks a significant operational deficit, as the net income stands at -$30.375M, revealing a cost structure where expenses substantially exceed gross earnings. Despite the net loss, the enterprise maintains an EBITDA of $12.78M, suggesting that while accounting measures like depreciation and amortization impact net income, the core operating cash generation before those non-cash items remains positive. However, the free cash flow is reported at -$16.58225M, which indicates a current lack of financial flexibility as the company is consuming cash to fund its operations and growth initiatives. Margin analysis highlights a complex profitability picture, with a gross margin of 70.2% indicating strong pricing power or low cost of goods sold relative to revenue, contrasted sharply by an operating margin of -105.2% and a profit margin of -25.6% that reflect high overhead costs or significant one-time charges impacting the bottom line. The balance sheet presents a leveraged position with total debt of $40.25M against cash reserves of $63.41M, resulting in a debt-to-equity ratio of 42.84, which suggests the company utilizes substantial leverage relative to its shareholder equity. Liquidity is supported by a current ratio of 1.70, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return metrics further illustrate the financial strain, with a return on equity of -28.3% and a return on assets of -3.9%, signaling that management has not yet generated positive returns on the capital deployed by shareholders or the asset base.
Valuation Assessment
Valuation metrics present a dichotomy between traditional earnings multiples and forward-looking expectations, with a trailing P/E ratio of N/A due to the recent net losses, while the forward P/E stands at 2.70, implying the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is recorded at 1.33, suggesting that the market values the company at 33% above its net asset value, which may reflect intangible assets, brand value, or potential in the pharmaceutical pipeline not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1.05 and an EV/EBITDA of 7.97 provide context for the stock's pricing relative to its revenue generation and enterprise earnings, indicating a valuation that is not excessively inflated given the current lack of net income. Price action shows the stock trading within a range defined by a 52-week high of $19.85 and a 52-week low of $7.65, meaning the current price sits at a level that reflects recent volatility and market sentiment shifts over the past year. The beta value of 0.79 indicates that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the overall index during periods of market fluctuation.
Growth & Income
Growth dynamics are characterized by a contraction in sales, with revenue growth year-over-year at -57.9%, while earnings growth is listed as N/A due to the absence of positive net income in the recent period. The negative revenue growth rate suggests a significant decline in sales volume or pricing power compared to the prior year, which is a primary driver of the financial challenges reflected in the net income figures. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available earnings, albeit negative in this instance, to fund operations rather than distributing income to shareholders. This reinvestment approach is typical for early-stage or turnaround pharmaceutical companies, but the current trajectory of negative growth and negative net income suggests that capital is being consumed to sustain the business rather than being deployed to generate immediate shareholder returns.